Hexarelin 5mg· 5mg

Hexarelin engages the growth hormone secretagogue receptor type 1a (GHSR-1a) on pituitary somatotrophs and hypothalamic neurons, activating Gq-mediated phospholipase C signaling and elevating intracellular calcium to stimulate growth hormone secretion. The methylated tryptophan residue at position 2 enhances receptor binding affinity and provides resistance to proteolytic degradation relative to GHRP-6.

A distinguishing feature of hexarelin pharmacology is its reported binding to CD36, a class B scavenger receptor expressed in cardiac myocytes, macrophages, and other tissues. This interaction has been proposed to mediate cardioprotective effects observed in ischemia-reperfusion models, including preservation of left ventricular function and reduction of infarct size. The cardiac actions of hexarelin appear partially distinct from its growth hormone-releasing properties, providing a rationale for ongoing research into the broader pharmacology of CD36-targeted peptides.